ACELYRIN INC. - COMMON STOCK

ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients

11 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

15 Feb 2024 16:05:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

20 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program

27 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights

07 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer

06 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023

31 Oct 2023 16:30:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development

03 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa

11 Sep 2023 16:05:00 By Nasdaq GlobeNewswire